Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Graft-versus-host Disease (GvHD)
93%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
60%
Acute Myeloid Leukemia
59%
Post-transplantation Cyclophosphamide (PTCy)
52%
Hematopoietic Cell Transplantation
44%
Unrelated Donor
37%
Haploidentical
37%
Donor Age
35%
Hazard Ratio
35%
Overall Survival
34%
Confidence Interval
34%
Non-relapse Mortality
32%
Myelodysplastic Syndrome
26%
Transplantation
22%
Busulfan
21%
High Risk
21%
Natural Killer Cells
19%
Donor Type
18%
Graft-versus-host Disease Prophylaxis
18%
Unrelated Hematopoietic Stem Cell Transplantation
18%
Haploidentical Donor
17%
Older Patients
16%
HLA-matched Donor
15%
Fludarabine
15%
Multiple Myeloma
15%
Transplant Outcomes
14%
Conditioning Regimen
14%
Haploidentical Hematopoietic Stem Cell Transplantation
13%
Cord Blood
13%
Cord Blood Transplantation
13%
Mismatched Related Donor
13%
Autologous Transplantation
12%
Myeloablative
12%
Peripheral Blood
12%
Matched Unrelated
12%
Progression-free Survival
12%
Matched Related
11%
Relapse-free Survival
11%
Engraftment
11%
Hematological Malignancies
10%
Multivariate Analysis
10%
Lower Gastrointestinal Tract
10%
Unrelated Donor Transplantation
9%
Bone Marrow
9%
Donor Selection
9%
Clonal Hematopoiesis
9%
Donor Groups
9%
Improved Outcomes
8%
Haploidentical Transplantation
8%
Tacrolimus
8%
Medicine and Dentistry
Hematopoietic Cell
85%
Cell Transplantation
81%
Acute Myeloid Leukemia
52%
Overall Survival
44%
Graft Versus Host Reaction
40%
Myelodysplastic Syndrome
31%
Transplantation
31%
Acute Graft Versus Host Disease
30%
Cyclophosphamide
30%
Hazard Ratio
26%
Chronic Graft Versus Host Disease
24%
Multiple Myeloma
19%
Conditioning
18%
Progression Free Survival
17%
Cord Blood
17%
Stem Cell Transplant
16%
Malignant Neoplasm
16%
Busulfan
16%
Donor Selection
15%
Diseases
13%
Fludarabine
13%
Recurrence Free Survival
12%
Alternative Donor
12%
Allograft
10%
Acute Lymphoblastic Leukemia
10%
Natural Killer Cell
9%
Comorbidity
9%
Cytomegalovirus
9%
Hematopoietic Stem Cell Transplantation
9%
Hematopoiesis
9%
Cord Blood Stem Cell Transplantation
9%
Cancer
9%
Multivariate Analysis
9%
Acute Myelogenous Leukemia
9%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Engraftment
8%
Non-Relapse Mortality
8%
Allogeneic Stem Cell Transplantation
8%
Prophylaxis
7%
Acute Leukemia
7%
Melphalan
6%
Leukemia
6%
Venetoclax
6%
Autotransplantation
6%
Chimeric Antigen Receptor
6%
Bronchiolitis Obliterans
6%
T Cell
6%
Mortality Rate
6%
Clinical Trial
5%
Cohort Analysis
5%
Immunology and Microbiology
Hematopoietic Cell
100%
Cell Transplantation
89%
Graft-Versus-Host Disease
68%
Cyclophosphamide
58%
Overall Survival
40%
Myeloid
39%
Chronic Graft Versus Host Disease
34%
Acute Graft Versus Host Disease
32%
Conditioning
28%
Cord Blood Stem Cell Transplantation
28%
Natural Killer Cell
24%
Engraftment
20%
Progression Free Survival
18%
Donor Selection
16%
Multiple Myeloma
15%
Umbilical Cord Blood
14%
Cytomegalovirus
13%
Allograft
12%
Recurrence Free Survival
12%
Platelet
11%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Neutrophil
9%
Immune Reconstitution
8%
Tacrolimus
7%
Drug Megadose
7%
Killer-Cell Immunoglobulin-Like Receptor
7%
Hematopoietic Stem Cell Transplantation
6%
Peptides
6%
Allogeneic Stem Cell Transplantation
6%
Haplotype
6%
Chimeric Antigen Receptor
6%
Human Leukocyte Antigen
6%
B Cell
6%
T Cell
5%